# A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT07881432
- Published: 2026-10-19
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07881432
- Source URL: https://clinicaltrials.gov/study/NCT07881432
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity. Participation in the study will last about 2 years.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: AMPLIFY-1
- status: NOT_YET_RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 2115
- sponsor: Eli Lilly and Company
- conditions: Obesity
- interventions: DRUG: eloralintide and tirzepatide; DRUG: Eloralintide; DRUG: Tirzepatide; DRUG: Placebo
- start date: 2026-12-01
- start date type: ESTIMATED
- primary completion date: 2029-10-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.